Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 264
Selected: 0
NCT IDTitle
NCT05582122SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
NCT05552001Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
NCT05296746Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
NCT00423475Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
NCT05800275Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
NCT03848052Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
NCT01376752Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
NCT03013335Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT01717924Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
NCT06505018Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
NCT02194842Phase III Radium 223 mCRPC-PEACE III
NCT01548677Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
NCT05440396Identifying Local Signs at the Catheter Insertion Site With Artificial Intelligence
NCT00104741Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
NCT06653777Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
NCT05973864Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT03518606Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
NCT02363049Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer
NCT02215265Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT06867705Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
NCT02701907EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies
NCT07118800Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
NCT00629616Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
NCT00190385Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis
NCT07262489Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
NCT01675999Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
NCT02947685Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02404935Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)
NCT00055679Combination Chemotherapy in Treating Women With Stage I Breast Cancer
NCT04747054Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
NCT07193394Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
NCT00287846Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
NCT00423696Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
NCT07340567Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test
NCT01143285Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer
NCT04790253PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
NCT04428047Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma
NCT01805271Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
NCT03676257Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
NCT00861094Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
NCT00104624Docetaxel in Treating Older Women With Metastatic Breast Cancer
NCT02827201FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine
NCT01165385Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
NCT00955240Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
NCT05443087TARGETed Therapy Drug MONITOring in DIGestive Oncology
NCT06528353Blood Biomarkers Based Screening for HPV-driven OPC
NCT03870919Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
NCT03672331My Personalized Breast Screening
NCT00112658Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
NCT07360743Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels